Evidence map›Paper›PMID 23303344›Full record

ArticleJAMA ophthalmology2013

Attenuation of choroidal neovascularization by β(2)-adrenoreceptor antagonism.

Jeremy A Lavine, Yanzhi Sang, Shoujian Wang, Michael S Ip, Nader Sheibani

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAMA ophthalmology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 46 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jeremy A LavineDepartments of Ophthalmology and Visual Science, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA.
Yanzhi Sang
Shoujian Wang
Michael S Ip
Nader Sheibani
University of Wisconsin–Madison · US

Funding

UW Vision Research Core - Administrative CoreP30EY016665 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI AKIHIRO IKEDA · 2005 to 2026
$12.6M
Integrated Multidisciplinary Strategies for Detection of Diabetic RetinopathiesRC4EY021357 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI ASSADI, AMIR H, ASSADI-PORTER, FARIBA M · 2010 to 2010
$3.2M
PECAM-1 and Retinopathy of PrematurityR01EY016695 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI SHEIBANI, NADER · 2007 to 2011
$1.6M
NEI NIH HHS EY016995NEI NIH HHS EY021357NEI NIH HHS P30 EY016665NEI NIH HHS P30-EY016665NEI NIH HHS R01 EY016695NEI NIH HHS RC4 EY021357
6 · The paper itself

Abstract

objectivesTo determine whether β-adrenergic blockade inhibits choroidal neovascularization (CNV) in a mouse model of laser-induced CNV and to investigate the mechanism by which β-adrenoreceptor antagonism blunts CNV.

designMice were subjected to laser burns, inducing CNV, and were treated with daily intraperitoneal injections of propranolol hydrochloride. Neovascularization was measured on choroidal-scleral flat mounts using intercellular adhesion molecule 2 immunofluorescence staining. The effect of β-adrenoreceptor signaling on expression of vascular endothelial growth factor (VEGF) was investigated using primary mouse choroidal endothelial cells (ChECs) and retinal pigment epithelial (RPE) cells. These cells were incubated with β-adrenoreceptor agonists and/or antagonists and assayed for Vegf messenger RNA and protein levels.

settingUniversity of Wisconsin School of Medicine and Public Health.

participantsWild-type 6-week-old female C57BL/6j mice.

main outcome measuresInhibition of CNV after propranolol treatment and Vegf messenger RNA and protein expression after treatment with β-adrenoreceptor agonists and antagonists.

resultsPropranolol-treated mice demonstrated a 50% reduction in laser-induced CNV. Treatment with norepinephrine bitartrate stimulated Vegf messenger RNA expression and protein secretion in ChECs and RPE cells. This effect was blocked by β2-adrenoreceptor antagonism and mimicked by β2-adrenoreceptor agonists.

conclusionsAttenuation of CNV is achieved by β-adrenergic blockade. The β2-adrenoreceptors regulate VEGF expression in ChECs and RPE cells. CLINICAL RELEVANCE: Antagonists of β-adrenoreceptors are safe and well tolerated in patients with glaucoma and cardiovascular disease. Thus, blockade of β-adrenoreceptors may provide a new avenue to inhibit VEGF expression in CNV.

Indexed as

Disease Models, AnimalAdrenergic beta-1 Receptor AgonistsAdrenergic beta-2 Receptor AgonistsAdrenergic beta-2 Receptor AntagonistsAnimalsCells, CulturedChoroidChoroidal NeovascularizationEndothelium, VascularFemaleMiceMice, Inbred C57BLPropranololReceptors, Adrenergic, beta-2Retinal Pigment EpitheliumReverse Transcriptase Polymerase Chain ReactionAdrenergic beta-1 Receptor AgonistsAdrenergic beta-2 Receptor AgonistsAdrenergic beta-2 Receptor AntagonistsPropranololReceptors, Adrenergic, beta-2RNA, MessengerVascular Endothelial Growth Factor Avascular endothelial growth factor A, mouse

Identifiers

PMID23303344
PMCPMC3652586
OpenAlexW2039366720

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.